Hepatitis C genotype 4: What we know and what we don't yet know

Hepatology

Volumn 47, Issue 4, 2008, Pages 1371-1383

  Kamal, Sanaa M ^a   Nasser, Imad A ^b  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; AMANTADINE; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

CLINICAL STUDY; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE COURSE; DRUG MEGADOSE; ETHNICITY; EVOLUTION; GENOTYPE; HEPATITIS C; HISTOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LOW DRUG DOSE; MEDICAL RESEARCH; MONOTHERAPY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT DURATION; TREATMENT OUTCOME; VIROLOGY;

CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER NEOPLASMS; LIVER TRANSPLANTATION;

EID: 42249110672     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22127     Document Type: Review

References (99)

1. NIH Consens State Sci Statements. 2002 Jun 10-12;19(3):1-46.
2. Robertson B, Myers G, Howard C, Brettin T, Bukh J, Gaschen B, et al. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for srandardization. International Committee on Virus Taxonomy. Arch Virol 1998;143:2493-2503.
3. Hnatyszyn HJ. Chronic hepatitis C and genotyping: the clinical significance of determining HCV genotypes. Antiviral Ther 2005;10:1-11.
4. World Health Organization. Hepatitis C. WHO fact sheet 164. Available at: http://www.who.int/mediacentre/factsheets/fs164/en/print.html. Accessed May 21, 2007.
5. Nguyen MH, Keeffe EB. Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin Gastroenterol Hepatol 2005;3(Suppl 2):S97-S101.
6. Egyptian Ministry of Health. Egyptian Ministry of Health Annual Report: 2007. Available at http://www.mohp.gov.eg/Main.asp. Accessed 10 August 2007.
7. Abdel-Aziz F, Habib M, Mohamed MK, Abdel-Hamid M, Gamil F, Madkour S, et al. Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. HEPATOLOGY 2000;32:111-115.
8. Rapicetta M, Argentini C, Dettori S, Spada E, Pellizzer G, Gandin C. Molecular heterogeneity and new subtypes of HCV genotype 4. Res Virol 1998;149:293-297.
9. Simmonds P, McOmish F, Yap PL, Chan S-W, Lin CK, Dusheiko G, et al. Sequence variability in the 5′ non-coding region of hepatitis C virus : identification of a new virus type and resttictions on the sequence diversity. J Gen Virol 1993;74:661-668.
10. Simmonds P, Holmes EC, Cha T-A, Chan SW, McOmish F, Irvine B, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993;74:2391-2399.
11. Bhattacherjee V, Prescott LE, Pike I, Rodgers B, Bell H, El-Zayadi AR, et al. Use of NS-4 peptides to identify type specific antibody to hepatitis C virus genotypes 1, 2, 3, 4, 5 and 6. J Gen Virol 1995;76:1737-1748.
12. Chamberlain R, Adams N, Saeed AA, Simmonds P, Elliott RM. Complete nucleotide sequence of a type 4 hepatitis C virus variant, the predominant genotype in the Middle East. J Gen Virol 1997;78:1341-1347.
13. Los Alamos National Laboratory. Los Alamos HCV Database. Available at: http://hcv.lanl.gov/content/hcvdb/classification/genotable.html. Accessed 9 August 2007.
14. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. HEPATOLOGY 2005;42:962-973.
15. Timm J, Neukamm M, Kuntzen T, Kim A, Chung R. T, Brander C, et al. Characterization of full-length hepatitis C virus genotype 4 sequences J Viral Hepat 2007;14:330-337.
16. Simmonds P. Genetic diversity and evolution of hepatitis C virus - 15 years on. J Gen Virol 2004;85:3173-3188.
17. Smith DB, Pathirana S, Davidson F, Lawlor E, Power J, Yap PL, et al. The origin of hepatitis C virus genotypes. J Gen Virol 1997;78:321-328.
18. Roulot D, Bourcier V, Grando V, Deny P, Baazia Y, Fontaine H, et al.; Observational VHC4 Study Group. Epidemiological charactetistics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat 2007;14:460-467.
19. Abdel Hamid M, El Daly M, Molnegren V, El-Kafrawy S, Abdel-Latif S, Esmat G, et al. Genetic diversity in hepatitis C virus in Egypt and possible association with hepatocellular carcinoma. J Gen Virol 2007;88:1526-1531.
20. Shoukry NH, Grakoui A, Houghton M, Chien DY, Ghrayeb J, Reimann KA, et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 2003;197:1645-1655.
21. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000;191:1499-1512.
22. Genovese D, Dettori S, Argentini C, Villano U, Chionne P, Angelico M, et al. Molecular epidemiology of hepatitis C virus genotype 4 isolates in Egypt and analysis of the variability of envelope proteins E1 and E2 in patients with chronic hepatitis. J Clin Microbiol 2005;43:1902-1909.
23. Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL. Genetic epidemiology of hepatitis C virus throughout Egypt. J Infect Dis 2000;182:698-707.
24. Xu L-Z, Larzul D, Delaporte E, Bréchot C, Kremsdorf D. Hepatitis C virus genotype 4 is highly prevalent in central Africa (Gabon). J Gen Virol 1994;75:2393-2398.
25. Ndjomou J, Pybus OG, Matz B. Phylogenetic analysis of hepatitis C virus isolates indicates a unique pattern of endemic infection in Cameroon. J Gen Virol 2003;84:2333-2341.
26. Njouom R, Nerrienet E, Dubois M, Lachenal G, Rousset D, Vessière A, et al. The hepatitis C virus epidemic in Cameroon: genetic evidence for rapid transmission between 1920 and 1960. Infect Genet Evol 2007;7:361-367.
27. Pybus O, Drummond A, Nakano T, Robertson BH, Rambaut A. The epidemiology and iatrogenic transmission of hepatitis C virus in Egypt: a Bayesian coalescent approach. Mol Biol Evol 2003;20:381-387.
28. Tanaka Y, Agha S, Saudy N, Kurbanov F, Orito E, Kato T, et al. Exponential spread of hepatitis C virus genotype 4a in Egypt. J Mol Evol 2004;58:191-195.
29. Angelico M, Renganathan E, Gandin C, Fathy M, Profili MC, Refai W, et al. Chronic liver disease in the Alexandria governorate, Egypt: contribution of schistosomiasis and hepatitis virus infections. J Hepatol 1997;26:236-243.
30. Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C in Egypt. Lancet 2000;355:887-891.
31. Kamal S, Madwar M, Bianchi L, Tawil AE, Fawzy R, Peters T, et al. Clinical, virological and histopathological features: long-term follow-up in patients with chronic hepatitis C co-infected with S. mansoni. Liver 2000;20:281-289.
32. Habib M, Mohamed MK, Abdel-Aziz F, Magder LS, Abdel-Hamid M, Gamil F, et al. Hepatitis C virus infection in a community in the Nile Delta: risk factors for seropositivity. HEPATOLOGY 2001;33:248-253.
33. Zakaria S, Fouad R, Shaker O, Zaki S, Hashem A, El-Kamary SS, et al. Changing patterns of acute viral hepatitis at a major urban referral center in Egypt. Clin Infect Dis 2007;44:e30-e36.
34. Stoszek SK, Abdel-Hamid M, Narooz S, El Daly M, Saleh DA, Mikhail N, et al. Prevalence of and risk factors for hepatitis C in rural pregnant Egyptian women. Trans R Soc Trop Med Hyg 2006;100:102-107.
35. El Katsha S, Labeeb S, Watts S, Younis A. Informal health providers and the transmission of hepatitis C virus: pilot study in two Egyptian villages. East Mediterr Health J 2006;12:758-767.
36. Talaat M, Kandeel A, El-Shoubary W, Bodenschatz C, Khairy I, Oun S, et al. Occupational exposure to needlestick injuries and hepatitis B vaccination coverage among health care workers in Egypt. Am J Infect Control 2003;31:469-474.
37. Kamal SM, Amin A, Madwar M, Graham CS, He Q, Al Tawil A, et al. Cellular immune responses in seronegative sexual contacts of acute hepatitis C patients. J Virol 2004;78:12252-12258.
38. Magder LS, Fix AD, Mikhail NN, Mohamed MK, Abdel-Hamid M, Abdel-Aziz F, et al. Estimation of the risk of transmission of hepatitis C between spouses in Egypt based on seroprevalence data. Int J Epidemiol 2005;34:160-165.
39. Mohamed MK, Abdel-Hamid M, Mikhail NN, Abdel-Aziz F, Medhat A, Magder LS, et al. Intrafamilial transmission of hepatitis C in Egypt. HEPATOLOGY 2005;42:683-687.
40. Shobokshi OA, Serebour FE, Skakni L, Al-Saffy YH, Ahdal MN. Hepatitis C genotypes and subtypes in Saudi Arabia. J Med Virol 1999;58:44-48.
41. Payan C, Roudot-Thoraval F, Marcellin P, Bled N, Duverlie G, Fouchard-Hubert I, et al. Changing of hepatitis C virus genotype patterns in France at the beginning of the third millennium: the GEMHEP GenoCII Study. J Viral Hepat 2005;12:405-413.
42. Nicot F, Legrand-Abravanel F, Sandres-Saune K, Boulestin A, Dubois M, Alric L, et al. Heterogeneity of hepatitis C virus genotype 4 strains circulating in south-westetn France. J Gen Virol 2005;86:107-114.
43. Ansaldi F, Bruzzone B, Salamaso S, Rota MC, Durando P, Gasparini R, et al. Different seroprelavence and molecular epidemiology pattern of hepatitis C virus infection in Italy. J Med Virol 2005;76:327-332.
44. Katsoulidou A, Sypsa V, Tassopoulos NC, Boletis J, Karafoulidou A, Ketikoglou I, et al. Molecular epidemiology of hepatitis C virus (HCV) in Greece: temporal trends in HCV genotype-specific incidence and molecular characterization of genotype 4 isolates. J Viral Hepat 2006;13:19-27.
45. Fernandez-Arcas N, Lopez-Siles J, Trapero S, Ferraro A, Ibanez A, Orihuela F, et al. High prevalence of hepatitis C virus subtypes 4c and 4d in Malaga (Spain): phylogenetic and epidemiological analyses. J Med Virol 2006;78:1429-1435.
46. Franco S, Tural C, Clotet B, Martínez MA. Complete nucleotide sequence of genotype 4 hepatitis C viruses isolated from patients co-infected with human immunodeficiency virus type 1. Virus Res 2007;123:161-169.
47. Lyra AC, Ramrakhiani S, Bacon BR, Di Bisceglie AM. Infection with hepatitis C virus genotype 4 in the United States. J Clin Gastroenterol 2004;38:68-71.
48. Zein N, Rakela J, Krawitt E, Reddy KR, Tominaga T, Persing DH. Heparitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Ann Int Med 1996;125:634-639.
49. Seeff L. Natural history of chronic hepatitis C. HEPATOLOGY 2002;36(Suppl 1):S35-S46.
50. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001;34:764-767.
51. De Moliner L, Pontisso P, De Salvo GL, Cavalletto L, Chemello L, Alberti A. Serum and liver HCV RNA levels in patients with chronic hepatitis C: correlation with clinical and histological features. Gut 1998;42:856-860.
52. Roffi L, Ricci A, Ogliari C, Scalori A, Minola E, Colloredo G, et al. HCV genotypes in Northern Italy: a survey of 1368 histologically proven chronic hepatitis C patients. J Hepatol 1998;29:701-706.
53. Harris HE, Eldridge KP, Harbour S, Alexander G, Teo CG, Ramsay ME. The HCV National Register Steering Group*. Does the clinical outcome of hepatitis C infection vary with the infecting hepatitis C virus type? J Viral Hepat 2007;14:213-220.
54. Kamal SM, Moustafa KN, Chen J, Fehr J, Abdel Moneim A, Khalifa KE, et al. Duration of peginterferon therapy in acute hepatitis C: a randomized trial. HEPATOLOGY 2006;43:923-931.
55. Santantonio T, Medda E, Ferrari C, Fabris P, Cariti G, Massari M, et al. Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy. Clin Infect Dis 2006;43:1154-1159.
56. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acure hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006;13:34-41.
57. Kamal SM, Rasenack JW, Bianchi L, Al Tawil A, El Sayed Khalifa K, Peter T, et al. Acute hepatitis C without and with schistosomiasis: corrlation with hepatitis C-specific CD4(+) T-cell and cytokine response. Gastroenterology 2001;121:646-656.
58. Gambotti L, Batisse D, Colin-de-Verdiere N, Delaroque-Astagneau E, Desenclos JC, Dominguez S, et al.; Acute Hepatitis C Collaborating Group. Acute hepatitis C infection in HIV positive men who have sex with men in Paris, France, 2001-2004. Euro Surveill 2005;10:115-117.
59. Kamal SM, Graham CS, He Q, Bianchi L, Tawil AA, Rasenack JW, et al. Kinetics of intrahepatic hepatitis C virus (HCV)-specific CD4+ T cell responses in HCV and Schistosoma mansoni coinfection: relation to progression of liver fibrosis. J Infect Dis 2004;189:1140-1150.
60. Kamal SM, Turner B, He Q, Rasenack J, Bianchi L, Al Tawil A, et al. Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis. HEPATOLOGY 2006;43:771-779.
61. Esmat G, Metwally M, Zalata KR, Gadalla S, Abdel-Hamid M, Abouzied A, et al. Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C. J Hepatol 2007;46:620-627.
62. Maida I, Soriano V, Barreiro P, Rivas P, Labarga P, Núñez M. Liver fibrosis srage and HCV genotype distribution in HIV-HCV coinfected patients with persisrenrly normal transaminases. AIDS Res Hum Retroviruses 2007;23:801-804.
63. Tsochatzis E, Papatheodoridis GV, Manesis EK, Chrysanthos N, Kafiri G, Petraki K, et al. Hepatic steatosis in genotype 4 chronic heparitis C is mainly because of metabolic factors. Am J Gastroenterol 2007;102:634-641.
64. Zayadi A, Attia M, Barakat EM, Zalata K, Saeid A, Hamdy H, et al. Non-alcoholic fatty liver disease in patients with HCV genotype 4. Gut 2007;56:1170-1171.
65. Kamal SM, El Kamary SS, Shardell MD, Hashem M, Ahmed IN, Muhammadi M, et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologic response. HEPATOLOGY 2007;46:1732-1740.
66. Lonardo A, Loria P, Adinolfi LE, Carulli N, Ruggiero G, et al. Hepatitis C and steatosis: a reappraisal. J Viral Hepat 2006;13:73-80.
67. Patel K, Zekry A, McHurchison JG. Steatosis and chronic hepatitis C virus infection: mechanisms and significance. Clin Liv Dis 2005;9:399-410.
68. Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, et al.; HCV Meta-Analysis (on) Individual Patients' Data Study Group. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006;130:1636-1642.
69. Zein NN, Poterucha JJ, Gross JB Jr, Wiesner RH, Therneau TM, Gossard AA, et al. Increased risk of heparocellular carcinoma in patients infected with hepatitis C genotype 1b. Am J Gastroenterol 1996;91:2560-2562.
70. Tanaka K, Ikematsu H, Hirohata T, Kashiwagi S. Hepatitis C virus infection and risk of hepatocellular carcinoma among Japanese: possible role of type 1b (II) infection. J Natl Cancer Inst 1996;88:742-746.
71. Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, Mondelli M. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. HEPATOLOGY 2007;46:1350-1356.
72. National Cancer Registry of Egypt. Magnitude of hepatocellular carcinoma in Egypt. Available at: http://www.nci.edu.eg. Accessed 3 August 2007.
73. Freedman LS, Edwards BK, Ries LAG, Young JL, eds. Cancer Incidence in Four Member Countries (Cyprus, Egypr, Israel, and Jordan) of the Middle East Cancer Consortium (MECC) Compared with US SEER. NIH Pub. No. 06-5873. Bethesda, MD: National Cancer Institute; 2006.
74. Ezzat S, Abdel-Hamid M, Eissa SA, Mokhtar N, Labib NA, El-Ghorory L, et al. Associations of pesticides, HCV, HBV, and hepatocellular carcinoma in Egypt. Int J Hyg Environ Health 2005;208:329-339.
75. Sugo H, Balderson GA, Crawford DH, Fawcett J, Lynch SV, Strong RW, et al. The influence of viral genotypes and rejection episodes on the recurrence of hepatitis C after liver transplantation. Surg Today 2003;33:421-425.
76. Gordon FD, Poterucha JJ, Germer J, Zein NN, Batts KP, Gross JB Jr, et al. Relationship between hepatitis C genotype and severity of recurrent hepatitis C after liver transplantation. Transplantation 1997;63:1419-1423.
77. Zekry A, Whiting P, Crawford DH, Angus PW, Jeffrey GP, Padbury RT, et al. Liver transplantation forHCV associated liver cirrhosis: Predictors of outcomes in a population with significant genotype 3 and 4 distribution. Liver Transpl 2003;9:339-347.
78. Wali MH, Heydtmann M, Harrison RF, Gunson BK, Mutimer DJ. Outcome of liver transplantation for patients infected by hepatitis C, including those infected by genotype 4. Liver Transplantation 2003;9:796-804.
79. Zylberberg H, Chaix ML, Brechot C. Infection with hepatitis C virus genotype 4 is associated with a poot response ro interferon-alpha. Ann Intern Med 2000;132:845-846.
80. Kamal SM, Madwar MA, Peters T, Fawzy R, Rasenack J. Interferon therapy in patients with chronic hepatitis C and schistosomiasis. J Hepatol 2000;32:172-174.
81. Koshy A, Marcellin P, Martinot M, Madda JP. Improved response to ribavirin inrerferon combination compared with interferon alone in patients with type 4 chronic heparitis C without cirrhosis. Liver 2000;20:335-339.
82. Alfaleh FZ, Hadad Q, Khuroo MS, Aljumah A, Algamedi A, Alashgar H, et al. Peginterferon a-2b plus ribavirin compared with interferon a-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver Int 2004;24:568-574.
83. Esmat G, Abouzied AM, Abdel-Aziz F, Strickland T. Subjects with chronic hepatitis C and genotype 4 have a similarly effective response to standard or pegylated interferon in combination with ribavirin [Abstract]. HEPATOLOGY 2003;38(Suppl):324A.
84. Shobokshi OA, Serebour FE, Skakni L, Al Khalifa M. Combination therapy of peginterferon alfa-2a and ribavirin significantly enhance sustained virological and biochemical response rate in chronic hepatitis C genotype 4 patients in Saudi Arabia [Abstract]. HEPATOLOGY 2003;38(Suppl):996A.
85. Thakeb FAI, Omar MM, El Awadi MM, Isshak SY. Randomized controlled trial of peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus genotype 4 among Egyptian patients [Abstract]. HEPATOLOGY 2003;38:252A.
86. Hasan F, Asker H, Al-Khaldi J, Siddique I, Al-Ajmi M, Owaid S, et al. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol 2004;99:1733-1737.
87. Diago M, Hassanein T, Rodes J, Ackrill AM, Sedarati F. Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-alpha2a and ribavirin. Ann Intern Med 2004;140:72-73.
88. Khuroo MS, Khuroo MS, Dahab ST. Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. Aliment Pharmacol Ther 2004;20:931-938.
89. Kamal SM, El Tawil AA, Nakano T, He Q, Rasenack J, Hakam SK, et al. Peginterferon alpha-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gur 2005;54:858-866.
90. El Zayadi AR, Attia M, Barakat EM, Badran HM, Hamdy H, El-Tawil A, et al. Response of hepatitis C genotype-4 naive patients to 24 weeks of peg-interferon-a2b/ribavirin or induction-dose interferon a2b/ribavirin/ amantadine: a non-randomized controlled study. Am J Gastroenterol 2005;100:2447-2452.
91. Derbala MF, Al Kaabi SR, El Dweik NZ, Pasic F, Butt MT, Yakoob R, et al. Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: impact of bilharziasis and fibrosis stage. World J Gastroenterol 2006;12:5692-5698.
92. Trapero-Marugan M, Moreno-Monteagudo JA, Garcia-Buey L, Borque MJ, Medina J, Garcia-Sanchez A, et al. Clinical and pathological characteristics and response to combination therapy of genotype 4 chronic hepatitis C patients: experience from a Spanish center. J Chemother 2007;19:423-427.
93. Legrand-Abravanel F, Nicor F, Boulestin A, Sandres-Saune K, Vinel JP, Alric L, et al. Pegylated inrerferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection. J Med Virol 2005;77:66-69.
94. Soriano V, Nunez M, Sanchez-Conde M, Barreiro P, Garcia-Samaniego A, Martin-Carbonero L, et al. Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4. Antiviral Ther 2005;10:167-170.
95. Fontana RJ, Everson GT, Tuteja S, Vargas HE, Shiffman ML. Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis. Clin Gastroenterol Hepatol 2004;2:183-197.
96. Buti M, Medina M, Casado MA, Wong JB, Fosbrook L, Esteban R. A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Aliment Pharmacol Ther 2003;17:687-694.
97. Wong JB, Nevens F. Cost-effectiveness of peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin as initial treatment of chronic hepatitis C in Belgium. Acta Gastroenterol Belg 2002;65:110-111.
98. Buti M, Casado MA, Fosbrook L, Esteban R. Financial impact of two different ways of evaluating early virological response to peginterferon-alpha- 2b plus ribavirin therapy in trearment-naive patients with chronic hepatitis C virus genotype 1. Pharmacoeconomics 2005;23:1043-1055.
99. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006;44:97-103.